Neuralink Stock: How to Invest Before the IPO

By Jon Quast – Updated Sep 12, 2024 at 9:04 AM

Key Points

Neuralink's N1 device, aiming to restore mobility and vision, could impact millions.
Neuralink is not publicly traded, limiting direct investment opportunities.
Invest indirectly via Alphabet stock to gain exposure to Neuralink advancements.

Investors naturally want to know everything about Neuralink stock because it's a headline-grabbing startup founded by Elon Musk. The medical device company specializes in brain-computer interface technology that potentially has far-reaching applications.

A brain-computer interface device is physically inserted into the brain to read signals and make them available for computers -- this is called "electrophysiological recording" in the trade. The technology isn't new, and multiple companies have performed human trials in the past with varying degrees of success. That said, Neuralink's design decisions could advance the technology.Elon Musk's Investment Strategy

Loading paragraph...

Doctors looking at scanned brain images. — Image source: Getty Images.

Loading paragraph...

IPO

IPO (Initial Public Offering) is the first sale of stock by a private company to the public, making it a publicly traded entity.

Loading paragraph...

Opportunity Cost

Opportunity cost refers to what you miss out on by going with one option over another comparable option.

Loading paragraph...

Exchange-Traded Fund (ETF)

An exchange-traded fund, or ETF, allows investors to buy many stocks or bonds at once.

Loading paragraph...

The bottom line on Neuralink

Neuralink believes it can restore lost mobility and vision through its brain-computer interface technology. These are big issues that could potentially make Neuralink a big business in the future. However, for now, the company isn't public, so investors can't buy stock. Even if it were public, it would still be a speculative investment opportunity, and shareholders would need a healthy appreciation of risk.

Loading paragraph...

Loading faq...

About the Author

Jon Quast is a contributing writer for The Motley Fool covering consumer goods, technology, and cryptocurrency. Before The Motley Fool, he was a missionary in South America.

TMFJaguar

@TMFJaguar

Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Jon Quast has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Intuitive Surgical, Nvidia, and Tesla. The Motley Fool has a disclosure policy.